Objective: To determine factors associated with baseline neurocognitive performance in HIVinfected participants enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) neurology substudy.
performance would be superior in patients receiving continuous ART via its attendant benefits upon both peripheral and CNS immunity.
We present a cross-sectional analysis of 292 HIV-infected persons coenrolled in the SMART neurology substudy at sites in Australia, North America, Brazil, and Thailand. We sought to explore factors associated with neurocognitive performance. These included demographics, ART, HAD, and cardiovascular risk factors and cardiovascular disease (CVD). In HIV-negative populations, smoking, 4 hypertension, 5 high cholesterol, 6 obesity, 5 and diabetes 5 are the cardiovascular risk factors associated with increased risk of poor cognitive function, vascular dementia, and Alzheimer disease (AD). Prior myocardial infarction, 7 coronary artery bypass grafting, 8 and stroke 5 are also associated with poor cognitive function. In HIV-positive populations, diabetes has been associated with HAD, 9 and increased carotid intima media thickening 10 has been associated with poorer neurocognitive performance. CVD risk factors were common in the SMART study 3 : we hypothesized that they would be associated with lower baseline neurocognitive performance. We sought to describe and compare neuropsychological test results obtained in Australia, North America, Brazil, and Thailand and hypothesized that test scores, but not the standardized z scores, would differ across locations.
METHODS Study design. The SMART study was an international randomized trial comparing continuous ART with CD4-cell count guided, intermittent ART in HIV-infected persons with CD4 cell count Ͼ350 cells/mm 3 . The neurocognitive component of the SMART neurology substudy aimed to compare the 2 study arms for changes in neurocognitive function through follow-up. Baseline, month 6, and annual assessment of neurocognitive functioning in 600 participants would have provided 80% power to detect a difference of 0.27 in the primary outcome (change in the aggregate quantitative neurocognitive performance z score, QNPZ-5, described below). The neurology substudy commenced enrollment in July 2005. In January 2006, enrollment and the intermittent CD4-guided ART strategy of the SMART study were stopped due to increased risk of AIDS and serious non-AIDS complications. The primary results of the SMART study are published elsewhere. 3 At the time of this protocol change, only 292 of the 600 planned substudy participants were enrolled, and minimal follow-up data were available.
Forty-seven SMART study sites in Australia, North America, Brazil, and Thailand participated in the substudy. All eligible SMART participants were offered substudy coenrollment. Substudy eligibility criteria included age Ն18 years, and the ability to perform the study's neurocognitive tests in the site clinician's judgment.
Standard protocol approvals, registrations, and patient consents. Substudy approval was obtained by each site's institutional review board. Patient information and consent forms were translated into Thai, Portuguese, and Spanish, and backtranslated into English. All participants provided written informed consent. The study was registered at clinical trials.gov: NCT00432003.
Outcome measures. The study's neurocognitive test battery comprised the Grooved Pegboard (GPB) (dominant hand), 11 Color Trails (CT) 1 and CT2, 12 Timed Gait (TG), 13 and Finger Tapping Test (FTT) (nondominant hand).
14 Details of these tests can be found in appendix e-1 on the Neurology ® Web site at www.neurology.org. This test battery was chosen because it is sensitive to changes observed in HIV-associated neurocognitive disorders, brief, easy to administer and teach, and can be used internationally where little formal Western education exists 15 ; our tests closely resemble the battery used in a large, randomized ART HIV treatment study. 16 For all 5 tests, the raw scores of each participant were standardized to z scores by subtracting the mean test scores of matched, HIV-negative reference populations, and dividing by the reference SD. Therefore, z scores estimate how many SDs a test score is above or below the average score of the reference population; negative z scores denote below-average performance. For the TG, raw scores were standardized to z scores using previously published reference distributions, 13 matched by education level. For the other tests, z scores were calculated using scoring software by Psychological Assessment Resources, Inc., Odessa, FL. 17 Reference distributions were matched by education level for all 5 tests, and additionally by age, sex, and race/ethnicity for GPB and FTT, 18 and by age for CT. All reference populations were obtained in the United States.
Our primary neurocognitive performance outcome measure was the QNPZ-5, calculated as the average of the 5 z scores from the individual tests in the battery. A QNPZ-5 score below 0 denotes below-average neurocognitive performance. For the purpose of this study, we defined neurocognitive impairment (NCI) as z scores ϽϪ2 in at least 2 cognitive ability domains. Ability domains assessed were 1) speed/fine motor skills (GPB and FTT), 2) attention/ speed of processing (CT1), 3) abstraction/executive function (CT2), and 4) gross motor skills (TG). The cutoff was chosen to reflect criteria for abnormal neurocognitive performance that are a required component for the diagnosis of HAD. 19 We administered the Center for Epidemiologic Studies-Depression scale (CES-D) 20 to screen for depression at baseline. The CES-D has been used in international studies in HIV-infected 15 populations. We used the recommended cutoff score of Ն16 to define depression (sensitivity 86%-100%, specificity 53%-84%). 21 Neuropsychological tests and the CES-D were administered to participants by site staff, including medical practitioners, specialists, and nurses. Site staff underwent centralized training and certification in the United States and Australia. Training was led by a neuropsychologist or neurologist and an infectious disease physician. Each trainee was required to administer the full test battery during training, and at least 3 times afterwards to nonstudy participants before administering it to study participants. Test instructions and training materials were available for site staff on the study Web site. Neuropsychological test instructions were translated into Portuguese, Spanish, and Thai. We used published translations of the Spanish 22 and Brazilian Portuguese 23 CES-D and an online Thai 24 translation.
Baseline data collected within the parent SMART study included demography, HIV history, general medical history, and laboratory values (summarized in table 1 and table e-1); additionally, alcohol and drug use were collected within the substudy. We summarized risk factors for CVD into a modified Framingham score; since blood pressure (BP) was not available, we assigned a systolic BP of 140 mm Hg to participants using antihypertensive drugs, and 120 mm Hg otherwise. 25 We calculated the CNS penetration effectiveness rank 26 of patients' ART regimens. Associations of baseline factors with raw test scores, z scores, the QNPZ-5 score, and having z scores ϽϪ2 in 2 or more cognitive domains (a total of 12 outcomes) were determined by multiple linear or logistic regression. In a first step, the following factors were included: HAD risk factors (age, current and nadir CD4 cell counts, prior AIDS, diabetes); sex; race/ethnicity; location of enrollment; education; body mass index; smoking; alcohol abuse; recreational drug use; history of hepatitis B, hepatitis C, or CVD; viral load (HIV RNA Յ400 copies/mL); CNS penetration effectiveness rank; use of BP-lowering and lipidlowering drugs; total cholesterol, high-density lipoprotein, and low-density lipoprotein; and CES-D score Ն16. Factors were then eliminated using backwards selection with the Akaike information criterion. We retained age, gender, race, and education in all models, because these factors were associated with neuropsychological test results in noninfected populations, and reference norms for calculating z scores are usually matched by these factors. We also retained location to consistently assess the location effect. Coefficients and p values from the final models were presented. In a separate model, lipids and use of BP-lowering drugs were replaced by Framingham risk estimates for CVD (4 categories), 25 extrapolating BP from use of BP-lowering drugs. Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC) and R version 2.9. All tests were 2-sided. p Values Յ0.05 were considered significant. Table 2 also shows the variability in test scores between clinical sites (between-site SD) in relation to the between-patient SD, estimated in hierarchical mixed models. For all tests except GPB, the between-site SD was about one-third to one-half of the between-patient SD, and remaining differences between locations (countries) were not statistically significant relative to the differences between sites (p Ͼ 0.05 in the hierarchical models).
RESULTS
The mean CES-D score was 11.2. Overall, 71 participants (26%) met the study definition of depression (table 2). The proportion of participants with depression was highest in Australia/North America (41%) and lowest in Thailand (14%). the QNPZ-5 scores, differed by location after adjustment for age, gender, race/ethnicity, education, and selected other factors ( (table 3) . Prior CVD was also associated with lower QNPZ-5 scores (by Ϫ0.7; p ϭ 0.02), as were use of antihypertensive agents (by Ϫ0.4, p ϭ 0.03), higher total cholesterol (by Ϫ0.03 per 10 mg/ mL, p ϭ 0.02), and hepatitis B (by Ϫ0.7, p ϭ 0.05); estimated mean QNPZ-5 scores were lower for women, black participants, and, borderline, for those with depression ( p ϭ 0.07) (table 3) . Smoking, diabetes, higher body mass index, higher low-density lipoprotein, and use of lipid-lowering drugs were not independently associated with NCI or lower QNPZ-5 scores but were associated with lower z scores or worse test scores for some of the tests (table  3 and table e-2) . Higher high-density lipoprotein was associated with lower z scores on GPB and CT1, but not with NCI or QNPZ-5 scores. In a sensitivity analysis, we included the Framingham CVD risk score as a factor instead of fitting cholesterol and BPlowering drugs separately: there was no evidence for an association of the Framingham score with either the QNPZ-5 or NCI (data not shown). There was no evidence that major abnormalities on the baseline ECG, hepatitis C, or alcohol abuse were independently associated with any of the neurocognitive performance measures (table 3, footnote).
There was no evidence for an association of baseline or nadir CD4 cell counts, viral load, diabetes, or the CNS penetration effectiveness rank of ART regimens with QNPZ-5 scores or NCI.
DISCUSSION Our cross-sectional study of baseline neurocognitive performance included 292 SMART study participants from Australia, North America, Brazil, and Thailand with CD4 cell counts Ͼ350 cells/mm 3 . At baseline, 14% of participants had NCI and prior CVD was the single associated factor. Participants with prior CVD, higher total cholesterol, and those using antihypertensive drugs had lower estimated mean baseline neurocognitive performance, but neither HIV-related risk factors commonly associated with HAD nor the CNS penetration effectiveness rank of ART were associated with NCI or neurocognitive performance measured by the QNPZ-5. The 10 participants (3.4%) with prior CVD in our study had experienced myocardial infarction, coronary heart disease, congestive heart failure, or peripheral vascular disease, but not stroke.
Our findings suggest that cardiovascular risk factors and disease may be key drivers of impairment in HIV-positive persons with high CD4 cell counts, more so than HIV-related HAD risk factors. These findings are important because HIVpositive populations have a high number of CVD risk factors including smoking, 3 hypertension, 3 diabetes, 3 hyperlipidemia, 3 metabolic syndrome, 27 insulin resistance, 28 and antiretroviral use. 29 The mechanisms that might link lower neurocognitive performance with CVD and cardiovascular risk factors in HIV-positive populations are likely multifactorial. In HIV-negative populations increasing evidence suggests that cardiovascular risk factors contribute to the pathogenesis of both vascular dementia and AD. [4] [5] [6] 30 Theoretically the pathogenesis of these 2 dementing illnesses may overlap. Recently it was proposed that insulin resistance, which underlies several of the abovementioned cardiovascular risk factors, may be one of the primary convergent mechanisms that links these risk factors to both vascular dementia and AD. 31 Raised inflammatory markers, including IL-6 and C-reactive protein, are risk factors for dementia 32 and are common to CVD, 33 the metabolic syndrome, 34 aging, and HIV, including treated HIV infection. 35 However, we do not have inflammatory markers for study analysis. The changes in the adaptive immune system of HIV-infected patients receiving long-term antiretroviral therapy resemble those seen in the elderly. 36 Key factors that may contribute to immune senescence in HIV-infected patients include persistent immune activation, inflammation, and poor CD4 cell response to antiretroviral treatment. 36 A recent study of HIVinfected patients measured coronary artery calcium accumulation and found an increased vascular age in over 40% of patients, with a mean increase of 15 years over their chronological age. 37 Increased vascular aging would help to explain why we found an association between lower neurocognitive performance and cardiovascular risk factors/CVD in a relatively young study population whereas cognitive decline and dementia associated with these factors in HIV-negative populations usually do not occur until at least the sixth decade. Similarly, the early expression of Parkinson disease in HIV infection has been reported recently. 38 None of the conventional HIV-related HAD risk factors was associated with NCI or lower neurocogni- For each outcome, associations with factors were determined in 2 steps: 1) starting from a comprehensive model with all factors, potentially relevant factors in addition to age, gender, race, education, and location were selected by backwards variable selection; 2) a model containing only the selected factors was fitted. All factors that had significant associations with NCI, the QNPZ-5 score, or at least 2 of the z scores were included in the table. Multiple regression coefficients with p values Յ0.10 were displayed, the remaining factors were labeled NS for nonsignificant; factors excluded by the backwards selection procedure were denoted by -.
b
Additionally to the factors shown in the table, the comprehensive model contained the following: CD4 cell count, HIV RNA Յ400 copies/mL, smoking, body mass index, diabetes mellitus, low-density lipoprotein, lipid-lowering drugs, recreational drug use (these factors were not significantly associated with NCI or the QNPZ-5 score, but had p Յ 0.10 for at least 1 of the neurocognitive tests; details are shown in table e-2); CNS penetration effectiveness rank of the participants' ART; major ECG abnormality at baseline, hepatitis C, CD4 count nadir, alcohol abuse (no significant associations of any of these factors with any of the outcomes).
c Neurocognitive impairment was defined as a z score ϽϪ2 on at least 2 tests from independent domains. p Values and coefficients were obtained by logistic regression; the coefficient of 2.3 for black race, for example, indicates that for black participants, the odds for the presence of NCI were 2.3 times higher than for nonblack participants, after adjustment for the other factors in the model. tive performance and the reason for this is unclear. The median CD4 cell count was high (536 cells/mm 3 ) but there was also no association of NCI with nadir CD4 counts. There was no evidence for an association of diabetes with impairment or poorer neurocognitive performance, although the lack of evidence may have been due to the low number of participants with diabetes. There was also no evidence for an association of the ART CNS penetration effectiveness rank with any of the neurocognitive performance scores. ART regimens with CNS penetration effectiveness ranks Ն2 have been associated with improved neurocognitive performance 26 ; in our study, 25% of participants had CNS penetration effectiveness ranks Ն2. Contrary to expectations, participants with prior AIDS had a slightly increased estimated mean QNPZ-5 score (by 0.24, p ϭ 0.05, table 3). This may be a statistical artifact due to confounding; in univariate analysis, those with and without prior AIDS had similar QNPZ-5 scores (p ϭ 0.60 for difference), but those with prior AIDS had more CVD risk factors, including a higher body mass index (mean 25 vs 23) and more use of BP-lowering drugs (18% vs 9%).
Mean z scores differed significantly between locations for each of the 5 neurocognitive tests; moreover, differences between locations persisted after adjusting for differences in age, sex, race, and education and other factors (table 3) . At first glance, this leads to the hypothesis that the standard US norms were not appropriate for Brazil or Thailand. Within countries, however, z scores also varied considerably between clinical sites (table 2, hierarchical model). Further adjustment for age, race, sex, and education decreased between-site variability in raw test scores, but had only minimal effect on the between-site variability in z scores (data not shown). The latter suggests that our US norm z scores reasonably standardized the test scores for these 4 demographic factors, and that the remaining variability between countries may be largely due to other unmeasured factors such as nutritional status, urban vs rural residency, cultural/ethnic factors, and test administration. It may be that if we had been able to more accurately measure and adjust for the education of participants, for example by assessing their reading level 39 instead of using years of education, we may have seen less between-country variability.
Twenty-four percent of participants met the study definition of depression; this proportion is commensurate with some studies but lower than others. 15 Antidepressant use was not assessed.
One should interpret our study definition of NCI (z scores ϽϪ2 in 2 or more domains) with caution because 1) NCI was not confirmed clinically; 2) we used US norms in Brazilian and Thai populations; and 3) we assessed 4 cognitive domains only. 19 Moreover, NCI may not always represent HAD or other HIV-associated neurocognitive disorders because there is an overlap between the neurocognitive impairment associated with cerebrovascular disease 40 and HIV-associated CNS disease.
Study limitations include a moderate sample size, which limits the power to detect associations; a modest test battery; study-trained staff rather than neuropsychologists administering the neurocognitive tests; and the lack of local reference norms in Brazil and Thailand. Also, hypertension was not assessed directly, but extrapolated from the use of BP-lowering drugs. Finally, we evaluated multiple outcomes; some of the observed associations might be falsepositives, in particular where statistical significance was borderline.
Our findings suggest that, in HIV-infected persons with high CD4 cell counts, cardiovascularrelated insults may be more detrimental to neurocognitive functioning than factors more directly related to HIV. Given the high prevalence of cardiovascular risk factors in HIV-infected populations, this finding is important and warrants further investigation.
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